Over the Counter Drugs Market Size, Share and Forecast 2019-2026

SKU: DPC421 | Last Updated On: Oct 09 2019 | No. of Pages: 172 | Available Formats

In January 2019, Innovus Pharmaceuticals, Inc., an emerging commercial-stage pharmaceutical company, launched Xyralid® Suppositories, for the reduction of swelling of hemorrhoidal tissues and provides pain relief from burning, itching, and discomfort

Market Overview

The global over the counter drugs market size was worth $ XX billion in 2019 and is forecasted to reach $ XX billion by 2026, at a CAGR of XX% during the forecast period. Over-the-counter drugs are the medicines that are sold directly to a consumer without a prescription. The increasing number of patent expiries of the prescription drugs and inclination of key players towards OTC revenue generation is leading to the increased demand for OTC drugs. The advancement and growth in distribution channels like online pharmacies, departmental stores, supermarkets, and others is also expected to drive the market.

Over the Counter Drugs Market

Market Dynamics

Global over the counter drugs market growth is driven by the growing need for self-medication by the consumers, growing healthcare awareness among the consumers, rising geriatric population who are more susceptible to several ailments like joint pains, increasing patent expirations of the prescription drugs, cost-effectiveness of OTC drugs, inclination of pharmaceutical companies from prescription drugs to OTC Drugs, and the presence of digital marketing key trends.

 

The inclination of pharmaceutical companies towards OTC drugs from Rx drugs is expected to drive the OTC drugs market. The increasing patent expiration rate is resulting in switching from prescription to OTC by the key players as a counter-strategy. As per the Consumer Healthcare Products Association, in the US, approximately 106 ingredients, dosage strengths, indications have undergone a switch from prescription to OTC, translating to about 700 OTC products in the market. The economic benefits received from OTC drugs usage led to the savings on the drug cost and cost related to the clinical visit. Thus, it is significantly attributing to the market growth in the emerging economies.

 

However, substance abuse and less awareness, the risk associated with taking wrong and self-medication, stringent regulations are hampering the growth of the market. For instance, in October 2018, FDA shuts down OTC drug manufacturer with longstanding and pervasive CGMP and labeling issues.

 

Market Segmentation

Based on type, the global over the counter drugs market is segmented into Analgesics, Cold, Cough, and Flu products, Weight loss products, Gastrointestinal products, Skin products, Mineral and vitamin supplements, Sleeping aids, Ophthalmic products, and others.

 

The weight-loss products segment is expected to drive the market over the period of forecast. This is owing to the rising awareness of the general population about health and an increase in the consumption of junk food, which leads to a rise in lifestyle-related diseases. On April 14, 2019, Gelesis, a biotechnology company which develops first-in-class hydrogel therapeutics for the treatment of obesity and other chronic diseases related to the gastrointestinal (GI) tract, got US FDA approval for PLENITY™ (Gelesis100), as an aid in weight management in adults with a Body Mass Index (BMI) of 25–40 kg/m2, when used in conjunction with diet and exercise.

 

The VMS (vitamins, minerals, and supplements) segment is also growing at a significant CAGR over the forecast period. This is owing to the large customer base for various products under this category. OTC products for these conditions are more of precautious nature than that of treatment or cure. The major players are adopting different strategies, including acquisitions, product launch, expansion, mergers, and others, which are also accelerating the growth of the market. For instance, In November 2016, the German healthcare company Stada acquired UK VMS business Natures Aid for its high quality branded products and complementary fit with Thornton & Ross, its UK based OTC business. The acquisition moved them firmly into the natural health space. Also, Samworth Brothers acquired sports nutrition business Sci-MX in June 2015 intending to use their brand expertise to reinforce Sci-MX's market share and provide them with an entry point into the sports nutrition market.

Global Market Share of over the Counter drugs Market (%), By  Type

Based on the mode of intake, the global over the counter drugs market is segmented into Oral, Topical, and Parenteral.

 

Oral route of administration is the most preferred route of drug delivery owing to its advantages like safety, proper patient compliance, ease of ingestion, pain avoidance, and versatility to accommodate various types of drugs. One of the trends in oral OTC drugs market is the use of orally disintegrating technology, which offers ease of use and convenience. The orally disintegrating tablets (ODT) and powders (ODP) have become a preferred dosage form for consumers globally for medications in a variety of therapeutic areas. These include traditional over-the-counter (OTC) medicines like ibuprofen and acetaminophen, montelukast and olanzapine, and a variety of other drugs for indications such as migraine, sleeplessness, and erectile dysfunction.

 

Based on end-users, the global OTC Drugs market is segmented into Retail Pharmacies, Hospital Pharmacies, online pharmacies, and others.

 

Online sales segment of over the Counter drugs is changing the market, menacing major OTC drugs manufacturers and permitting minor companies to get their share in the market. Bayer's Aleve is one of the best-selling drugs in America with a revenue of around $485 million in case of sales in 2016. But there was a drop-in sale by 10% in 2017. This was attributable to the availability of alternative drugs online from small manufacturers. This shows that power is gradually shifting toward e-commerce, making it difficult for the major players.

 

Geographical Analysis

North America is dominating the global OTC drugs market in 2018 and estimated to hold largest market size over the forecast period (2019-2026) owing to the leading trend among pharmaceutical companies to switch from prescription to OTC drugs, increasing drug development, and ease of availability of the drugs.

 

According to the National Institute of Health, 93% of adults in the US prefer to treat their minor ailments with OTC medicines before seeking professional care, and 85% of parents in the US prefer to treat their children's small diseases with an OTC medicine before seeking professional care. 

 

In the US, there are around 100,000 OTC drug products marketed and sold in a variety of outlets, such as pharmacies and stores.

 

For example, proton pump inhibitors like esomeprazole (Nexium 24HR) and stomach acid blockers like ranitidine (Zantac 150), which are used for heartburn, are the examples of drug products which have made the Rx-to-OTC switch. The emergency contraceptive pill ("the morning-after pill") also known as Plan B One-Step is now available OTC without any age restriction and can be found on the shelves in many pharmacies in the U.S.

 

The presence of the vast number of OTC drugs generating significant revenues in the region is expected to boost the market. For instance, according to the Washington, D.C.-based non-profit Consumer Healthcare Protection Association, the top-selling OTC drug categories in 2018 (million) were Oral analgesics with $4,323, Heartburn with $3,229, Antiperspirants with $3,034, etc.

Global Over the Counter Drugs Market Share (%), By Geography, 2018

Competitive Landscape

  • Some of the key players in the global over the counter drugs market are Bayer HealthCare, Johnson and Johnson, Pfizer, Novartis, GlaxoSmithKline (GSK), Boehringer Ingelheim, Sanofi, Teva Pharmaceutical Industries Ltd., Alkem Laboratories Limited.
  • The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, which are contributing to the growth of the Over the Counter drugs market globally. For instance,
  • In January 2019, Innovus Pharmaceuticals, Inc., an emerging commercial-stage pharmaceutical company, launched Xyralid® Suppositories, for the reduction of swelling of hemorrhoidal tissues and provides pain relief from burning, itching, and discomfort. Xyralid® Suppositories received a Product License Application ("PLA") in Canada, and the product is available as an over-the-counter ("OTC") or behind the counter drug and will not require a prescription. The product is now available in Canada directly through the Company's website and its Beyond Human® marketing and sales platform.
  • In May 2019, Innovus Pharmaceuticals, Inc., announced that Taro Pharmaceuticals U.S.A., Inc., will supply Innovus Pharma, through the Company’s wholesaler, Taro’s 5% Minoxidil Foam for men and women under its approved ("ANDA") No. 209074 from the U.S. Food and Drug Administration ("FDA"). Innovus Pharma will launch the drug under its own trademark Regoxidine™.
  • On July 6, 2018, Pfizer announced that the MHRA had approved the reclassification of the proton pump inhibitor (PPI) Nexium Control (esomeprazole), making it available for the consumers to purchase it without a prescription.
  • In November 2018, Elite Pharmaceuticals, Inc. ("Elite" or the “Company"), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, launched generic methadone hydrochloride 5mg and 10 mg tablets by Glenmark Pharmaceuticals, Inc., USA (“Glenmark”), Elite’s marketing alliance partner.
  • In July 2018, Dr. Reddy's Laboratories (DRL) today launched over-the-counter Esomeprazole magnesium delayed-release capsules USP, 20 mg, used to treat acid reflux, in the US market. Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg is an over-the-counter (OTC) therapeutic equivalent generic version of Nexium 24 hour capsules.
  • In January 2018, J&J, GlaxoSmithKline and Reckitt Benckiser are on a race to buy Pfizer's $20 billion consumers. However, the final two competitors are Reckitt Benckiser and GSK.

 

Why Purchase the Report?

  • Visualize the composition of the global over the counter drugs market in terms of various types, mode of intake, and end-users highlighting the critical commercial assets and players.

  • Identify commercial opportunities in global over the counter drugs market by analyzing trends and co-development deals.

  • Excel data sheet with thousands of data points of global over the counter drugs market-level 4/5 segmentation.

  • A PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

  • Product mapping in excel for the key product of all major market players.

 

Target Audience

  • Service Providers/ Buyers

  • Industry Investors/Investment Bankers

  • Education & Research Institutes

  • Research Professionals

  • Emerging Companies

  • Manufacturers

 

  1. Global Over the Counter Drugs Market Methodology and Scope

    1. Research Methodology
    2. Research Objective and Scope of the Report
  2. Global Over the Counter Drugs Market – Market Definition and Overview

  3. Global Over the Counter Drugs Market – Executive Summary

    1. Market Snippet by Type
    2. Market Snippet by Mode of intake
    3. Market Snippet by End-users
  4. Global Over the Counter Drugs Market Dynamics

    1. Market Impacting Factors
      1. Drivers
        1. The inclination of pharmaceutical companies from prescription drugs into OTC drugs
      2. Restraints
        1. Stringent regulations
      3. Opportunity
      4. Impact Analysis
  5. Global Over the Counter Drugs Market – Industry Analysis

    1. Porter's Five Forces Analysis
    2. Regulatory Analysis
    3. Supply Chain Analysis
    4. Pricing Analysis
  6. Global Over the Counter Drugs Market – By Type

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type segment
      2. Market Attractiveness Index, By Type Segment
    2. Weight loss products *
      1. Introduction
      2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
    3. Analgesics
    4. Cold, cough and flu products
    5. Gastrointestinal products
    6. Skin products
    7. Mineral and Vitamin supplements
    8. Sleeping Aids
    9. Ophthalmic products
    10. Others
  7. Global Over the Counter Drugs Market – By Mode of intake

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of intake segment
      2. Market Attractiveness Index, By Mode of intake Segment
    2. Oral *
      1. Introduction
      2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
    3. Topical
    4. Parenteral
  8. Global Over the Counter Drugs Market – by End-User

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users Segment
      2. Market Attractiveness Index, By End-Users Segment
    2. Online pharmacies *
      1. Introduction
      2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
    3. Hospital pharmacies
    4. Retail pharmacies
    5. Others
  9. Global Over the Counter Drugs Market - By Region

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
      2. Market Attractiveness Index, By Region
    2. North America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of intake
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. The U.S.
        2. Canada
        3. Mexico
    3. Europe
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of intake
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Germany
        2. The U.K.
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
    4. South America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of intake
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Brazil
        2. Argentina
        3. Rest of South America
    5. Asia Pacific
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of intake
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. China
        2. India
        3. Japan
        4. Australia
        5. Rest of Asia Pacific
    6. The Middle East and Africa
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of intake
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  10. Global Over the Counter Drugs Market Competitive Landscape

    1. Competitive Scenario
    2. Market Positioning/Share Analysis
    3. Mergers and Acquisitions Analysis
  11. Global Over the Counter Drugs Market Company Profiles

    1. Bayer HealthCare *
      1. Company Overview
      2. Product Portfolio and Description
      3. Key Highlights
      4. Financial Overview
    2. Johnson and Johnson
    3. Pfizer
    4. Novartis
    5. GlaxoSmithKline (GSK)
    6. Boehringer Ingelheim
    7. Sanofi
    8. Teva Pharmaceutical Industries Ltd
    9. Alkem Laboratories Limited
  12. Global Over the Counter Drugs Market – Premium Insights

  13. Global Over the Counter Drugs Market – Data M

    1. Appendix
    2. About Us and Services
    3. Contact Us

LIST OF TABLES                                  

TABLE 01     GLOBAL OVER THE COUNTER DRUGS MARKET VALUE, BY TYPE, 2018,2022 & 2026 ($ MILLION)

TABLE 02     GLOBAL OVER THE COUNTER DRUGS MARKET VALUE, BY MODE OF INTAKE, 2018,2022 & 2026 ($ MILLION)

TABLE 03     GLOBAL OVER THE COUNTER DRUGS MARKET VALUE, BY END-USERS, 2018,2022 & 2026 ($ MILLION)

TABLE 04     GLOBAL OVER THE COUNTER DRUGS MARKET VALUE, BY REGION, 2018,2022 & 2026 ($ MILLION)

TABLE 05     GLOBAL OVER THE COUNTER DRUGS MARKET VALUE, BY COUNTRY, 2018,2022 & 2026 ($ MILLION)

TABLE 06     GLOBAL OVER THE COUNTER DRUGS MARKET VALUE, BY TYPE, 2018,2022 & 2026 ($ MILLION)

TABLE 07     GLOBAL OVER THE COUNTER DRUGS MARKET VALUE, BY TYPE, 2017-2026 ($ MILLION)

TABLE 08     GLOBAL OVER THE COUNTER DRUGS MARKET VALUE, BY MODE OF INTAKE, 2018,2022 & 2026 ($ MILLION)

TABLE 09     GLOBAL OVER THE COUNTER DRUGS MARKET VALUE, BY MODE OF INTAKE, 2017-2026 ($ MILLION)

TABLE 10     GLOBAL OVER THE COUNTER DRUGS MARKET VALUE, BY END-USERS, 2018,2022 & 2026 ($ MILLION)

TABLE 11     GLOBAL OVER THE COUNTER DRUGS MARKET VALUE, BY END-USERS, 2017-2026 ($ MILLION)

TABLE 12     GLOBAL OVER THE COUNTER DRUGS MARKET VALUE, BY REGION, 2018,2022 & 2026 ($ MILLION)

TABLE 13     GLOBAL OVER THE COUNTER DRUGS MARKET VALUE, BY REGION, 2017-2026 ($ MILLION)

TABLE 14     GLOBAL OVER THE COUNTER DRUGS MARKET VALUE, BY COUNTRY, 2018,2022 & 2026 ($ MILLION)

TABLE 15     GLOBAL OVER THE COUNTER DRUGS MARKET VALUE, BY COUNTRY, 2017-2026 ($ MILLION)

TABLE 16     NORTH AMERICA OVER THE COUNTER DRUGS MARKET VALUE, BY TYPE, 2017-2026 ($ MILLION)

TABLE 17     NORTH AMERICA OVER THE COUNTER DRUGS MARKET VALUE, BY MODE OF INTAKE, 2017-2026 ($ MILLION)

TABLE 18     NORTH AMERICA OVER THE COUNTER DRUGS MARKET VALUE, BY END-USERS, 2017-2026 ($ MILLION)

TABLE 19     NORTH AMERICA OVER THE COUNTER DRUGS MARKET VALUE, BY REGION, 2017-2026 ($ MILLION)

TABLE 20     NORTH AMERICA OVER THE COUNTER DRUGS MARKET VALUE, BY COUNTRY, 2017-2026 ($ MILLION)

TABLE 21     SOUTH AMERICA OVER THE COUNTER DRUGS MARKET VALUE, BY TYPE, 2017-2026 ($ MILLION)

TABLE 22     SOUTH AMERICA OVER THE COUNTER DRUGS MARKET VALUE, BY MODE OF INTAKE, 2017-2026 ($ MILLION)

TABLE 23     SOUTH AMERICA OVER THE COUNTER DRUGS MARKET VALUE, BY END-USERS, 2017-2026 ($ MILLION)

TABLE 24     SOUTH AMERICA OVER THE COUNTER DRUGS MARKET VALUE, BY REGION, 2017-2026 ($ MILLION)

TABLE 25     SOUTH AMERICA OVER THE COUNTER DRUGS MARKET VALUE, BY COUNTRY, 2017-2026 ($ MILLION)

TABLE 26     EUROPE OVER THE COUNTER DRUGS MARKET VALUE, BY TYPE, 2017-2026 ($ MILLION)

TABLE 27     EUROPE OVER THE COUNTER DRUGS MARKET VALUE, BY MODE OF INTAKE, 2017-2026 ($ MILLION)

TABLE 28     EUROPE OVER THE COUNTER DRUGS MARKET VALUE, BY END-USERS, 2017-2026 ($ MILLION)

TABLE 29     EUROPE OVER THE COUNTER DRUGS MARKET VALUE, BY REGION, 2017-2026 ($ MILLION)

TABLE 30     EUROPE OVER THE COUNTER DRUGS MARKET VALUE, BY COUNTRY, 2017-2026 ($ MILLION)

TABLE 31     ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET VALUE, BY TYPE, 2017-2026 ($ MILLION)

TABLE 32     ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET VALUE, BY MODE OF INTAKE, 2017-2026 ($ MILLION)

TABLE 33     ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET VALUE, BY END-USERS, 2017-2026 ($ MILLION)

TABLE 34     ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET VALUE, BY REGION, 2017-2026 ($ MILLION)

TABLE 35     ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET VALUE, BY COUNTRY, 2017-2026 ($ MILLION)

TABLE 36     MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET VALUE, BY TYPE, 2017-2026 ($ MILLION)

TABLE 37     MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET VALUE, BY MODE OF INTAKE, 2017-2026 ($ MILLION)

TABLE 38     MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET VALUE, BY END-USERS, 2017-2026 ($ MILLION)

TABLE 39     MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET VALUE, BY REGION, 2017-2026 ($ MILLION)

TABLE 40     MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET VALUE, BY COUNTRY, 2017-2026 ($ MILLION)

TABLE 41     BAYER HEALTHCARE: OVERVIEW                

TABLE 42     BAYER HEALTHCARE: PRODUCT PORTFOLIO         

TABLE 43     BAYER HEALTHCARE: KEY DEVELOPMENTS

TABLE 44     JOHNSON AND JOHNSON: OVERVIEW           

TABLE 45     JOHNSON AND JOHNSON   : PRODUCT PORTFOLIO 

TABLE 46     JOHNSON AND JOHNSON: KEY DEVELOPMENTS     

TABLE 47     PFIZER: OVERVIEW                             

TABLE 48     PFIZER: PRODUCT PORTFOLIO                      

TABLE 49     PFIZER: KEY DEVELOPMENTS                       

TABLE 50     NOVARTIS: OVERVIEW                       

TABLE 51     NOVARTIS: PRODUCT PORTFOLIO                

TABLE 52     NOVARTIS: KEY DEVELOPMENTS                 

TABLE 53     GLAXOSMITHKLINE: OVERVIEW                  

TABLE 54     GLAXOSMITHKLINE: PRODUCT PORTFOLIO            

TABLE 55     GLAXOSMITHKLINE: KEY DEVELOPMENTS            

TABLE 56     BOEHRINGER INGELHEIM  : OVERVIEW                  

TABLE 57     BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO   

TABLE 58     BOEHRINGER INGELHEIM: KEY DEVELOPMENTS   

TABLE 59     SANOFI: OVERVIEW                            

TABLE 60     SANOFI: PRODUCT PORTFOLIO                     

TABLE 61     SANOFI: KEY DEVELOPMENTS            

TABLE 62     TEVA PHARMACEUTICAL INDUSTRIES LTD: OVERVIEW   

TABLE 63     TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT PORTFOLIO

TABLE 64     TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY DEVELOPMENTS

TABLE 65     ALKEM LABORATORIES LIMITED: OVERVIEW        

TABLE 66     ALKEM LABORATORIES LIMITED: PRODUCT PORTFOLIO 

TABLE 67     ALKEM LABORATORIES LIMITED: KEY DEVELOPMENTS  

LIST OF FIGURES                                          

FIGURE 01      GLOBAL OVER THE COUNTER DRUGS MARKET SHARE, BY TYPE, 2018 & 2026 (%)

FIGURE 02      GLOBAL OVER THE COUNTER DRUGS MARKET SHARE, BY MODE OF INTAKE, 2018 & 2026 (%)

FIGURE 03      GLOBAL OVER THE COUNTER DRUGS MARKET SHARE, BY END-USERS, 2018 & 2026 (%)

FIGURE 04      GLOBAL OVER THE COUNTER DRUGS MARKET SHARE, BY REGION, 2018 & 2026 (%)

FIGURE 05      GLOBAL OVER THE COUNTER DRUGS MARKET SHARE, BY COUNTRY, 2018 & 2026 (%)

FIGURE 06      GLOBAL OVER THE COUNTER DRUGS MARKET VALUE, 2017-2026 ($ MILLION)

FIGURE 07      GLOBAL OVER THE COUNTER DRUGS MARKET Y-O-Y GROWTH, BY TYPE, 2018-2026 (%)

FIGURE 08      GLOBAL OVER THE COUNTER DRUGS MARKET Y-O-Y GROWTH, BY MODE OF INTAKE, 2018-2026 (%)

FIGURE 09      GLOBAL OVER THE COUNTER DRUGS MARKET Y-O-Y GROWTH, BY END-USERS, 2018-2026 (%)

FIGURE 10      GLOBAL OVER THE COUNTER DRUGS MARKET Y-O-Y GROWTH, BY REGION, 2018-2026 (%)

FIGURE 11      GLOBAL OVER THE COUNTER DRUGS MARKET Y-O-Y GROWTH, BY COUNTRY, 2018-2026 (%)

FIGURE 12      NORTH AMERICA OVER THE COUNTER DRUGS MARKET VALUE, 2017-2026 ($ MILLION)

FIGURE 13      NORTH AMERICA OVER THE COUNTER DRUGS MARKET SHARE, BY TYPE, 2018 & 2026 (%)

FIGURE 14      NORTH AMERICA OVER THE COUNTER DRUGS MARKET SHARE, BY MODE OF INTAKE, 2018 & 2026 (%)

FIGURE 15      NORTH AMERICA OVER THE COUNTER DRUGS MARKET SHARE, BY END-USERS, 2018 & 2026 (%)

FIGURE 16      NORTH AMERICA OVER THE COUNTER DRUGS MARKET SHARE, BY REGION, 2018 & 2026 (%)

FIGURE 17      NORTH AMERICA OVER THE COUNTER DRUGS MARKET SHARE, BY COUNTRY, 2018 & 2026 (%)

FIGURE 18      SOUTH AMERICA OVER THE COUNTER DRUGS MARKET VALUE, 2017-2026 ($ MILLION)

FIGURE 19      SOUTH AMERICA OVER THE COUNTER DRUGS MARKET SHARE, BY TYPE, 2018 & 2026 (%)

FIGURE 20      SOUTH AMERICA OVER THE COUNTER DRUGS MARKET SHARE, BY MODE OF INTAKE, 2018 & 2026 (%)

FIGURE 21      SOUTH AMERICA OVER THE COUNTER DRUGS MARKET SHARE, BY END-USERS, 2018 & 2026 (%)

FIGURE 22      SOUTH AMERICA OVER THE COUNTER DRUGS MARKET SHARE, BY REGION, 2018 & 2026 (%)

FIGURE 23      SOUTH AMERICA OVER THE COUNTER DRUGS MARKET SHARE, BY COUNTRY, 2018 & 2026 (%)

FIGURE 24      EUROPE OVER THE COUNTER DRUGS MARKET VALUE, 2017-2026 ($ MILLION)

FIGURE 25      EUROPE OVER THE COUNTER DRUGS MARKET SHARE, BY TYPE, 2018 & 2026 (%)

FIGURE 26      EUROPE OVER THE COUNTER DRUGS MARKET SHARE, BY MODE OF INTAKE, 2018 & 2026 (%)

FIGURE 27      EUROPE OVER THE COUNTER DRUGS MARKET SHARE, BY END-USERS, 2018 & 2026 (%)

FIGURE 28      EUROPE OVER THE COUNTER DRUGS MARKET SHARE, BY REGION, 2018 & 2026 (%)

FIGURE 29      EUROPE OVER THE COUNTER DRUGS MARKET SHARE, BY COUNTRY, 2018 & 2026 (%)

FIGURE 30      ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET VALUE, 2017-2026 ($ MILLION)

FIGURE 31      ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SHARE, BY TYPE, 2018 & 2026 (%)

FIGURE 32      ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SHARE, BY MODE OF INTAKE, 2018 & 2026 (%)

FIGURE 33      ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SHARE, BY END-USERS, 2018 & 2026 (%)

FIGURE 34      ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SHARE, BY REGION, 2018 & 2026 (%)

FIGURE 35      ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SHARE, BY COUNTRY, 2018 & 2026 (%)

FIGURE 36      MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET VALUE, 2017-2026 ($ MILLION)

FIGURE 37      MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SHARE, BY TYPE, 2018 & 2026 (%)

FIGURE 38      MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SHARE, BY MODE OF INTAKE, 2018 & 2026 (%)

FIGURE 39      MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SHARE, BY END-USERS, 2018 & 2026 (%)

FIGURE 40      MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SHARE, BY REGION, 2018 & 2026 (%)

FIGURE 41      MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SHARE, BY COUNTRY, 2018 & 2026 (%)

FIGURE 42      BAYER HEALTHCARE: FINANCIALS                      

FIGURE 43      JOHNSON AND JOHNSON   : FINANCIALS              

FIGURE 44      PFIZER: FINANCIALS                        

FIGURE 45      NOVARTIS: FINANCIALS                             

FIGURE 46      GLAXOSMITHKLINE: FINANCIALS             

FIGURE 47      BOEHRINGER INGELHEIM  : FINANCIALS             

FIGURE 48      SANOFI: FINANCIALS                                   

FIGURE 49      TEVA PHARMACEUTICAL INDUSTRIES LTD : FINANCIALS         

FIGURE 50      ALKEM LABORATORIES LIMITED: FINANCIALS   

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Get your FREE SAMPLE PROPOSAL with a single click!